Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a @entity19 model of XXXX .

@entity14018 @entity0 @entity19 @entity5 @entity15905
@entity14018 [Poly (I: C)], a ligand for Toll-like receptor ( @entity15905 ), is used as an adjuvant to enhance anti- @entity5 immunity because of its prominent effects on CD8 T cells and NK cells. Myeloid-derived suppressor cells (MDSCs) are one of the main immunosuppressive factors in @entity5 , and their abnormal accumulation is correlated with the clinical stage of @entity0 and is an important mechanism of @entity5 immune evasion. Although Poly (I: C) is thought to have direct anti- @entity5 activity in different cell lines, its effect on immunosuppressive MDSCs in @entity5 -bearing animals has not been studied. 4T1-Luc, a metastatic @entity0 @entity19 cell line, was injected into the left flank of female BALB/c @entity19 . Tumor-bearing @entity19 were treated with i.p. injection of Poly (I: C) or PBS beginning on day 7 after @entity5 inoculation. WBCs and MDSCs were counted using coulter counter and stained for flow cytometry, respectively. Bioluminescent imaging was used to monitor @entity5 burden at multiple time points during the course of @entity5 growth. Poly (I: C) treatment led to a decrease in MDSC frequencies in BM, blood, and @entity5 compared to saline-treated control @entity19 . Poly (I: C) treatment also abrogated the immunosuppressive function of MDSCs, concomitant with an increase in local T cell response of the immune system in a @entity19 model of @entity0 . Poly (I: C) treatment decreases MDSC frequency and immunosuppressive function in 4T1- @entity5 -bearing hosts and effectively augments the activity of @entity0 immunotherapy.
